Johan Pluvy | Thoracic Oncology News

New promising phase 1 study for lung cancer @NEJM * Zongertinib in HER2-Mutant NSCLC -ORR 76% (tumor shrinkage in most patients) -PFS 14.4 mo (disease control) -Brain mets: 47% response ✅

Biomarkers potential in early stages @HwakeleeMD at #ELCC2026 @OncoAlert

Today we're releasing 10 more future predictions from Warpspeed v1. Follow along over the next few months and see just how accurate we are: warpspeed.sh

🚨 1 in 7 NSCLC patients on first-line immunotherapy will develop severe toxicity And it begins early ➡️14% severe irAEs ➡️~70% within the first 3 months ➡️Median onset 1.4 months Risk ↑ ChT + ICI (HR 2.35) Pre-existing autoimmune disease (HR 1.25) Longer diagnosis to treatment interval (HR 1.50) Risk ↓ Atezolizumab vs pembrolizumab (HR 0.75) Nivolumab (HR 0.91) Lung, blood, GI, these lead (not rare, not late, and not random) The highest risk patients are already defined before treatment and show it within weeks doi.org/10.1038/s41598… @OncoAlert

Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. ja.ma/4167rLa

EGFR TKI was invented before discovery of EGFR driver mutations

How EGFR inhibitors transformed outcomes in EGFR-mutated non–small-cell lung cancer

Same feeling than you and Benjamin. Some patients also derived prolonged benefit from durva + ceralasertib in the Pioneer trial. Need to be investigated.

TOP : first prospective phase III trial showing osi plus CTx significantly prolongs PFS vs. osi monotherapy in advanced EGFRm NSCLC with TP53 co-mutations. mutations. PFS 34 m. vs 15.6 m. It reinforces the benefit of the combo in this high risk population. #ELCC2026 @OncoAlert

💯 Most exciting “sleeper” study at #ELCC26 waking us and CTLA-4 inhibition up again for a patient subset in great need for new options! One that if holds true in larger experience would definitely pass @PTarantinoMD ‘s 4-wheeled T-test!

Our paper is online @JTOonline Molecular Profiling across 80,000 Patients with Lung Cancer. A robust demonstration that we need to test all patients with NSCLC & ALL histologies and open the door for nomenclature change. jto.org/article/S1556-… @Al3ssandroRusso @OhioStateMedOnc

@NetCancerFrance L’attente en hdj est une véritable toxicité pour les patients ! Bravo pour ce concept de pré validation et cette coordination efficace et l’apport des IPA dans cette efficience. @NetCancerFrance

🕰️ Mme Angélique Dumont, IPA, nous présente l'organisation des immunothérapies dans son CHU. Ce sujet et bien d'autres sont explorés dans notre table ronde consacrée à la chronothérapie et son impact dans l'immunothérapie. Retrouvez le replay ici : netcancer.net/actualites/tab…

Very happy to share our work published in @lungcajournal Single-center retrospective cohort study of lung cancer associated with interstitial lung disease: Prognostic factors and molecular profile sciencedirect.com/science/articl…

@PascaleTomasini @LGreillier @EtienneGtn @AMogenetMD @aphm_actu @CHUdeMarseille @APHMtargetrials

Perspectives • Prospective real Life cohorts to improve LC-ILD guidelines and knowledge @TomPrt • Adapted prognostic scores (e.g., ILD-GAP cancer) • Integration of molecular data